Beigene Ltd (BGNE) Director Xiaodong Wang Sells 14,461 Shares of Stock

Beigene Ltd (NASDAQ:BGNE) Director Xiaodong Wang sold 14,461 shares of the company’s stock in a transaction dated Thursday, May 4th. The shares were sold at an average price of $40.80, for a total transaction of $590,008.80. Following the sale, the director now owns 65,030 shares of the company’s stock, valued at $2,653,224. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Xiaodong Wang also recently made the following trade(s):

  • On Wednesday, April 5th, Xiaodong Wang sold 11,650 shares of Beigene stock. The shares were sold at an average price of $36.83, for a total transaction of $429,069.50.
  • On Friday, March 24th, Xiaodong Wang sold 38,107 shares of Beigene stock. The stock was sold at an average price of $36.96, for a total transaction of $1,408,434.72.
  • On Friday, March 10th, Xiaodong Wang sold 36,892 shares of Beigene stock. The stock was sold at an average price of $39.89, for a total transaction of $1,471,621.88.
  • On Monday, February 27th, Xiaodong Wang sold 38,351 shares of Beigene stock. The stock was sold at an average price of $38.19, for a total transaction of $1,464,624.69.

Beigene (NASDAQ:BGNE) last released its quarterly earnings data on Wednesday, March 22nd. The company reported ($1.05) EPS for the quarter, missing analysts’ consensus estimates of ($0.86) by $0.19. The firm had revenue of $1 million for the quarter, compared to the consensus estimate of $3.75 million. During the same period in the prior year, the business earned ($3.05) EPS. The company’s revenue for the quarter was down 78.6% compared to the same quarter last year.

Insider Buying and Selling by Quarter for Beigene (NASDAQ:BGNE)

COPYRIGHT VIOLATION NOTICE: This article was published by Chaffey Breeze and is owned by of Chaffey Breeze. If you are reading this article on another website, it was stolen and reposted in violation of international trademark and copyright laws. The correct version of this article can be accessed at https://www.chaffeybreeze.com/2017/05/20/insider-selling-beigene-ltd-bgne-director-sells-590008-80-in-stock-updated.html.

Several institutional investors have recently added to or reduced their stakes in BGNE. Boxer Capital LLC raised its position in Beigene by 72.2% in the fourth quarter. Boxer Capital LLC now owns 850,000 shares of the company’s stock worth $25,806,000 after buying an additional 356,370 shares during the period. Guggenheim Capital LLC bought a new stake in shares of Beigene during the fourth quarter valued at about $670,000. Baillie Gifford & Co. raised its stake in shares of Beigene by 0.7% in the fourth quarter. Baillie Gifford & Co. now owns 69,284 shares of the company’s stock valued at $2,103,000 after buying an additional 449 shares during the last quarter. Baker BROS. Advisors LP bought a new stake in shares of Beigene during the third quarter valued at about $58,930,000. Finally, Hsbc Holdings PLC bought a new stake in shares of Beigene during the third quarter valued at about $636,000. Institutional investors own 33.01% of the company’s stock.

Several research firms recently issued reports on BGNE. Maxim Group set a $52.00 price target on shares of Beigene and gave the stock a “buy” rating in a research report on Saturday, March 11th. Zacks Investment Research lowered shares of Beigene from a “hold” rating to a “sell” rating in a report on Monday, March 27th.

About Beigene

BeiGene, Ltd. is a clinical-stage biopharmaceutical company. The Company is focused in the discovery and development of molecularly targeted and immuno-oncology drugs for the treatment of cancer. The Company had used its cancer biology platform to develop four clinical-stage drug candidates, such as BGB-3111, BGB-A317, BGB-290 and BGB-283, as of December 31, 2016.

12 Month Chart for NASDAQ:BGNE

Receive News & Ratings for Beigene Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Beigene Ltd and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply